Pharmacokinetics


 
LRRI has broad capabilities in determining the absorption, distribution, metabolism, and excretion of drug entities delivered by all exposure routes. We are internationally recognized for our capability to measure the dosimetry of inhaled agents. LRRI excels in the development and use of novel delivery, tracer, and analytical approaches to resolve dosimetric and metabolic questions, particularly those related to inhaled compounds.
 

 

Key Capabilities:

  • Complete range of dose-delivery modes: oral, intravenous, bolus, infusion
  • Complete range of laboratory animal species including primates and mini-pigs
  • Collection of blood, lymph, bile, and other fluids
  • Analysis of compound and metabolites in biological samples by LC-MS/MS and other modalities
  • Radioisotope studies: conduct of ADME in rodent and non-rodent species
  • Distribution of radiotracers by gamma scintigraphy, autoradiography, and radiochemical analyses
  • Iterative mathematical modeling of pharmacokinetics
  • Extensive analytical capability and alliances for all additional analyses
  • Extrapolation of human pharmacokinetics using physiologically based pharmacokinetics (PBPK) modeling
  • PK/PD modeling and regimen design

In Addition:

  • Compliance with FDA Good Laboratory Practice regulations and other customer requirements
  • Confidential, proprietary, and intellectual property agreements
  • Customer participation and collaboration on customer's in-house investigations

ACCESS LRRI PUBLICATIONS ON THIS TOPIC IN PUBMED